Oncology Central

3D tissue-engineered bone marrow: what does this mean for the treatment of multiple myeloma?


Multiple myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow (BM), which remains incurable because most patients relapse or become refractory to the treatments [1]. The American Cancer Society’s estimates for MM in the USA for 2016 about 30,000 new cases will be diagnosed and about 12,500 deaths will occur. Newly diagnosed MM patients with standard-risk disease are associated with a median overall survival of about 4 years, whereas high-risk disease MM patients are associated with a median overall survival of about 2 years [2].

Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.